Navigation Links
eResearchTechnology Reports Third Quarter 2008 Results
Date:10/30/2008

tire 2007 year. We were able to increase our third quarter operating income margin to 31.1% from 30.3% in the second quarter of 2008. Net income for the third quarter was $6.9 million, an increase of 87.0% from $3.7 million for the third quarter of 2007."

"We continue to execute very well on our projects," continued Dr. McKelvey. "We completed the integration of the CCSS acquisition, which was a tremendous accomplishment by our staff. Our sales force reports a healthy pipeline of new opportunities, reflecting the continued emphasis on cardiac safety and eRT's reputation for quality, medical and scientific leadership, project execution, and technology innovation. The pricing environment continues to be stable. In the current economic and financial environment, we feel that our strong balance sheet and cash flow, the continued importance of cardiac safety in clinical trials, and our established reputation for quality, project management, and cost-effective performance will be important contributors to our business going forward."

2008 Guidance

The Company issued guidance for the full year and fourth quarter of 2008. For the full year 2008, the Company is narrowing its revenue range and expects revenue of between $134.0 million and $137.0 million. The company is raising its guidance for diluted net income per share to between $0.47 to $0.50 for the full year 2008. The company's revenue guidance for the fourth quarter is between $31.0 to $34.0 million, and its guidance for diluted net income per share for the fourth quarter is between $0.10 and $0.13.

Conference Call

Dr. McKelvey and Keith Schneck, the Company's Chief Financial Officer, will hold a conference call to discuss these results. The conference call will take place at 5:00 p.m. EDT on October 30, 2008. Interested participants should call 1-866-277-1181 when calling within the United States or 617-597- 5358 when calling internationally. Please use pass code 54904519. There wil
'/>"/>

SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
2. eResearchTechnology to Present at the UBS Global Healthcare Services Conference 2008 on February 11th
3. eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
4. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
5. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
6. eResearchTechnology, Inc. to Announce 2008 First Quarter Results on May 5, 2008
7. eResearchTechnology to Present at the Deutsche Bank 33rd Annual Healthcare Conference on May 7th 2008
8. eResearchTechnology Reports First Quarter 2008 Results
9. eResearchTechnology Announces Resignation of its CFO
10. eResearchTechnology to Present at the FBR 12th Annual Spring Investor Conference on May 28th 2008
11. eResearchTechnology Names New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , Dec. 24, ... company advancing patient care in critical areas, announced the closing ... stock, and warrants to purchase up to an aggregate 3,500,000 ... per share and $.01 per warrant.  The warrants have a ...
(Date:12/24/2014)... 23, 2014 “Preparative & Process ... Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), ... Agriculture) - Forecasts to 2019” provides a detailed ... current market trends, and strategies impacting the preparative ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... designed to introduce cutting edge communication technology, provide ... platform upgrades. This webinar series demonstrates online communication ... to leverage web conferencing’s most innovative and powerful ...
(Date:12/24/2014)... The report provides basic information on ... and industry overview. This report also presents product ... is separated by regions, technology and applications. The ... client survey, marketing channels, industry development trend and ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... 19 New long-term data from two pivotal, Phase ... arthritis (RA) receiving SIMPONI (TM) (golimumab) every four ... physical function response through one year. These new ... of Rheumatology (ACR) Annual Scientific Meeting. , "New data ...
... , QUEBEC CITY, Oct. 19 /PRNewswire-FirstCall/ - AEterna ... (the "Company"), a global biopharmaceutical company focused on ... has initiated activities intended to complete the clinical ... ghrelin agonist compound macimorelin (AEZS-130) which could be ...
... Holdings, Inc. ("Cellu Tissue") today announced that it has filed a ... Commission (the "SEC") relating to a proposed initial public offering of ... shares to be sold by Cellu Tissue and shares to be ... shares to be offered, the allocation of shares to be sold ...
Cached Biology Technology:New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 2New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 3New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 4New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 5New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 6New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 7New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 8New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 9New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 10AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency 2AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency 3Cellu Tissue Holdings, Inc. Files Registration Statement for Proposed Initial Public Offering of Common Stock 2
(Date:12/17/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally ... for the first time a fingerprint sensor in its ...
(Date:12/17/2014)... SM announced today its completion of a Good ... current U.S. Food and Drug Administration (FDA) regulations. This ... smart phone application trials utilizing the highest principles for ... determined to improve global healthcare access, quality, and delivery ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in this market ... applications. Chemical sensors help in recording of patient data ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... births resulting from in-vitro-fertilization (IVF), researchers at Yale School ... that estimates the reproductive potential of individual embryos, possibly ... higher success rate in women undergoing IVF. , Over ... the United States. In 2002, 3.1 embryos on average ...
... approach can kill bacteria in laboratory experiments and eliminate ... bacterial nutrient, according to research led by a University ... UW, the University of Iowa, and the University of ... of the Journal of Clinical Investigation. , Bacteria ...
... of light are providing insight into the complexities of the ... of how the human brain works. , Investigators at Duke ... engineered a strain of mice whose olfactory brain cells "fire" ... the cells a gene naturally present in green algae that ...
Cached Biology News:Trojan horse strategy defeats drug-resistant bacteria 2Common algae helps illustrate mammalian brain electrical circuitry 2Common algae helps illustrate mammalian brain electrical circuitry 3
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
...
...
Recombinant Rat Fas Ligand/TNFSF6...
Biology Products: